


Novo Nordisk - update

Liver Forum – Washington DC

Michelle T. Long, MD, MSc


International Medical Vice President, MASH
March 6 2026



NN9500-7730: A clinical trial designed to address the unmet needs in ALD

- People with ALD have a **large unmet medical need** – there are **no approved medications** to treat this disease^{1–3}
- These patients often have a **high burden of cardiometabolic diseases**, contributing to adverse health outcomes^{3,4}
- There are both pre-clinical and clinical rationales supporting the rationale that **zalfermin**, **cagrilintide** and **semaglutide** may **improve liver damage** and **reduce alcohol intake**⁴
- These compounds are currently under development for use in **MASH** as well as other **cardiometabolic conditions**, and some are approved for use in the treatment of **type 2 diabetes** and for **weight management**⁴

Effects of NNC0194 -0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease



Study start : Q2 2024

Study completion : Q1 2026

Primary endpoint:

Change in ELF

Secondary Endpoints:

Change in Pro-C3

Change in VCTE

Change in CAP

Change in liver enzymes

Change in PEth

Change in alcohol use

TEAEs

...